Saleh M K, Malik W A, Ahmad B, Janbaz K H, Khan M A
Department of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
Pak J Pharm Sci. 1993 Jan;6(1):1-7.
The influence of ibuprofcn (400 mg urally) on the pharmacokinetics of isoniazid (500 mg orally) was evaluated in healthy human subjects (n = 30). Subjects participated in a two way crossover trial, the first dosing condition was isoniazid alone (control), and the second dosing condition was ibuprofen with isoniazid. The concentrations of isoniazid from the serum samples were determined by HPLC. The pharmacokinetic parameters show a significant (P.<0.05) increase in the area under the serum concentration/time curve (AUC) in both fast and slow acetylators of isoniazid, with a significant increase in the maximum serum concentration (C(max)) of isoniazid (only in slow acetylators with no effect on fast acetylators), a significant increase in the elimination half-life (t (1/2)), and the time for the maximum drug concentration (T(max)) (only in fast acetylators with no effect on slow acetylators).
在健康人体受试者（n = 30）中评估了布洛芬（400 mg口服）对异烟肼（500 mg口服）药代动力学的影响。受试者参与了一项两交叉试验，第一种给药情况是单独使用异烟肼（对照），第二种给药情况是布洛芬与异烟肼联用。通过高效液相色谱法测定血清样本中异烟肼的浓度。药代动力学参数显示，异烟肼的快乙酰化者和慢乙酰化者的血清浓度/时间曲线下面积（AUC）均显著（P<0.05）增加，异烟肼的最大血清浓度（C(max)）显著增加（仅在慢乙酰化者中，对快乙酰化者无影响），消除半衰期（t(1/2)）显著增加，以及药物达峰时间（T(max)）显著增加（仅在快乙酰化者中，对慢乙酰化者无影响）。
